2.23
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
GT Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GT Biopharma appoints new board member By Investing.com - Investing.com Nigeria
GT Biopharma (GTBP) Welcomes New Board Member Andrew Ritter | GTBP Stock News - GuruFocus
GT Biopharma Appoints New Member to its Board of Directors - The Manila Times
GT Biopharma appoints new board member - Investing.com
GT Biopharma Strengthens Board with Biotech Exit Expert Andrew Ritter: 3 Successful Company Sales - Stock Titan
GT Biopharma (GTBP) Appoints Hilary Kramer to Board of Directors - GuruFocus
GT Biopharma adds Hilary Kramer to Board of Directors By Investing.com - Investing.com Canada
GT Biopharma Appoints New Member To Its Board Of Directors - marketscreener.com
GT Biopharma adds Hilary Kramer to Board of Directors - Investing.com
$12B Portfolio Expert Hilary Kramer to Guide NK Cell Pioneer GT Biopharma's Clinical Expansion - Stock Titan
GT Biopharma (GTBP) Projected to Post Earnings on Wednesday - Defense World
GT Biopharma Board Restructures with New Appointments - TipRanks
GT Biopharma announces private placement deal - Investing.com
GT Biopharma Secures $5.45M in Private Placement - TipRanks
Nanobodies Market to Reach US$ 2.27 Billion by 2031: Growth - openPR.com
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
GT Biopharma (NASDAQ:GTBP) Trading Down 1.7% – Time to Sell? - The AM Reporter
Nanobodies Market Gains Momentum with Advancements in Immunotherapy | Ablynx, Sanofi, Merck - openPR.com
GT Biopharma Appoints Michael Breen as New CEO - TipRanks
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GT Biopharma, Inc. Announces Corporate Update Conference Call with CEO Dr. Kathleen Clarence-Smith, CMO Dr. Raymond Urbanski and Chairman Anthony Cataldo - ACCESS Newswire
Xeris Biopharma Holdings Inc (XERS) stock analysis: A simple moving average approach - uspostnews.com
GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire
GT Biopharma Announces Completion of $5.6 Million Bridge Financing - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Nanobodies Market Growth, Opportunities and Future Scope 2025-2032 | Merck KGaA, Sanofi, AlpalifeB Inc - newstrail.com
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - MSN
GT Biopharma Issues Warrant to Cytovance for Services Rendered - Investing.com Australia
GT Biopharma Issues Warrant to Cytovance for Services Rendered By Investing.com - Investing.com Canada
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order - Yahoo Finance
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
North American Morning Briefing : Stock Futures -2- - MarketScreener
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - MarketBeat
The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire
Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan
GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire
Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World
Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):